ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Tepoditamab Biosimilar - Anti-CLEC12A Antibody - Low endotoxin, Azide free (A323773)

Recombinant human monoclonal antibody to CLEC12A for ELISA, FACS, Functional Assay and In Vivo.

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 12-18 business days.
Name
Tepoditamab Biosimilar - Anti-CLEC12A Antibody - Low endotoxin, Azide free
Description
Recombinant human monoclonal antibody to CLEC12A.
Applications
ELISA, FACS, Functional Assay, In Vivo
Reactivity
Human, Cynomolgus Macaque
Host
Human
Clonality
Monoclonal
Isotype
IgG1
Light Chains
kappa
Conjugate

Unconjugated

Purification
Protein A affinity chromatography.
Concentration
Reconstitution dependent.
Molecular Weight
This antibody has a predicted MW of 144.73 kDa.
Purity
> 95% (by SDS-PAGE and SEC-HPLC).
Product Form
Lyophilized
Reconstitution
Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml concentration. Gently shake to solubilize completely. Do not vortex!
Formulation
Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.
Storage
Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at -80°C. Product is stable for one year. Avoid freeze/thaw cycles.
Synonyms
C-type lectin domain family 12 member A, C-type lectin-like molecule 1, CD371, CLL-1, CLL1, DCAL-2, DCAL2, Dendritic cell-associated lectin 2, MICL, Myeloid inhibitory C-type lectin-like receptor
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Tepoditamab Biosimilar - Anti-CLEC12A Antibody - Low endotoxin, Azide free (A323773)? Please let us know so that we can list the citation on this page.

Alternative products to Tepoditamab Biosimilar - Anti-CLEC12A Antibody - Low endotoxin, Azide free (A323773)

Proteins predicted to interact with CLEC12A

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
98.1% Relevancy Score
86% Relevancy Score
81.3% Relevancy Score
77% Relevancy Score
73.1% Relevancy Score
72.9% Relevancy Score
70.9% Relevancy Score
70.8% Relevancy Score
70.6% Relevancy Score